Liquidia Can Challenge 1 of 2 United Therapeutics’ Patents (2)

(Updates shares in second bullet and adds details in fifth and sixth bullets.)

• The Patent Trial and Appeal Board will review the validity of United Therapeutics’ patent 9,604,901 but not a related patent 9,593,066, according to status notifications on the board’s electronic docket.
• United Therapeutics shares rose 4.5% while Liquidia shed 26%
• Both patents are for a process to make treprostinil, the active ingredient in UTHR’s Remodulin and Tyvaso,
• UTHR said Liquidia was relying on invalidity arguments that had already been considered and rejected during the application process
• PTAB said at least two claims of the ‘901 patent are likely ...